LONDON (Alliance News) - Imperial Innovations Group PLC on Monday said its portfolio company Veryan Medical has completed patient enrolment into the MIMICS-2 clinical study.
Imperial has a 46.1% interest in Veryan Medical, with a net investment carrying value of GBP26.5 million.
The clinical study is designed to evaluate the safety and efficacy of Veryan's BioMimics 3D Self-Expanding Stent System in the treatment of patients with symptomatic femoropopliteal disease.
The study is being conducted under a US Food & Drug Administration "Investigational Device Exemption", with concurrence from the Japanese Pharmaceuticals & Medical Devices Agency, to provide data supporting future marketing applications for the system in both the US and Japan.
The BioMimics 3D system has already been awarded the CE Mark and is actively being sold in Europe.
Imperial said enrolment in the MIMICS-2 study has been concluded with a total of 271 patients enrolled across 47 investigational sites in Germany, the US and Japan.
"We are very pleased with the speed at which enrolment has been completed, which is a testament to the investigating physicians' enthusiasm for recruiting patients and the efficiency of the Veryan team," said Imperial Chief Investment Officer Nigel Pitchford.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
